Valuation: QuidelOrtho Corporation

Capitalization 74Cr 64Cr 58Cr 55Cr 101.61Cr 7.12TCr 103.35Cr 695.52Cr 269.56Cr 3.37TCr 277.42Cr 271.54Cr 12TCr P/E ratio 2026 *
-6.78x
P/E ratio 2027 * -8.92x
Enterprise value 305.05Cr 262.1Cr 239.81Cr 227.74Cr 419.34Cr 29TCr 426.49Cr 2.87TCr 1.11TCr 14TCr 1.14TCr 1.12TCr 48TCr EV / Sales 2026 *
1.12x
EV / Sales 2027 * 1.07x
Free-Float
99.18%
Yield 2026 *
-
Yield 2027 * -
1 day+5.04%
1 week+8.84%
Current month-11.87%
1 month-14.71%
3 months-55.13%
6 months-49.06%
Current year-62.04%
1 week 10.31
Extreme 10.31
11.67
1 month 9.92
Extreme 9.92
13.49
Current year 9.92
Extreme 9.92
35.58
1 year 9.92
Extreme 9.92
35.58
3 years 9.92
Extreme 9.92
90.45
5 years 9.92
Extreme 9.92
180.06
10 years 9.92
Extreme 9.92
306.72
Manager TitleAgeSince
Chief Executive Officer 61 06/05/2024
Director of Finance/CFO 58 -
Chief Operating Officer 57 15/11/2024
Director TitleAgeSince
Chairman 72 11/12/2022
Director/Board Member 71 01/01/2022
Director/Board Member 82 01/01/1993
Change 5d. change 1-year change 3-years change Capi.($)
+5.04%+8.84%-67.60%-87.54% 74Cr
+1.92%+4.69%-3.91%-35.00% 1.59TCr
-0.39%-1.78%+83.73%+87.37% 220.61Cr
+1.69%-1.00%-31.00%-8.21% 105.89Cr
-0.49%-8.56%-12.16%-50.66% 72Cr
-2.79%-4.50%-26.78%-50.11% 69Cr
-4.54%-14.26%+56.16% - 41Cr
+2.17%+6.14%-50.85%-56.87% 43Cr
+0.41%-0.05%+23.10%-55.69% 41Cr
+2.12%+5.56%-35.06%-33.83% 31Cr
Average +0.51%-1.68%-6.44%-32.28% 228.5Cr
Weighted average by Cap. +1.43%-0.71%+0.55%-25.18%

Financials

2026 *2027 *
Net sales 272.08Cr 233.78Cr 213.89Cr 203.13Cr 374.03Cr 26TCr 380.4Cr 2.56TCr 992.21Cr 12TCr 1.02TCr 999.5Cr 43TCr 281.47Cr 241.84Cr 221.27Cr 210.14Cr 386.92Cr 27TCr 393.52Cr 2.65TCr 1.03TCr 13TCr 1.06TCr 1.03TCr 45TCr
Net income -16Cr -14Cr -12Cr -12Cr -22Cr -1.52TCr -22Cr -148.2Cr -57Cr -717.89Cr -59Cr -58Cr -2.5TCr -8.31Cr -7.14Cr -6.53Cr -6.2Cr -11Cr -800.25Cr -12Cr -78Cr -30Cr -378.63Cr -31Cr -31Cr -1.32TCr
Net Debt 231.13Cr 198.59Cr 181.7Cr 172.56Cr 317.73Cr 22TCr 323.14Cr 2.17TCr 842.87Cr 11TCr 867.44Cr 849.06Cr 37TCr 225.91Cr 194.1Cr 177.6Cr 168.66Cr 310.56Cr 22TCr 315.85Cr 2.13TCr 823.84Cr 10TCr 847.85Cr 829.89Cr 36TCr
Logo QuidelOrtho Corporation
QuidelOrtho Corporation provides in vitro diagnostics, developing and manufacturing intelligent solutions. The Company specializes in immunoassay and molecular testing, clinical chemistry and transfusion medicine. Its business units include labs, molecular diagnostics, point of care and transfusion medicine. Under the labs business unit, its product categories include virology & bioassays, specialty products, VITROS platform and immunodiagnostics. Under the molecular diagnostics business unit, its product categories include Lyra, Solana and Savanna. Under the point of care business unit, its product categories include rapid immunoassay and cardiometabolic immunoassay. Under the transfusion medicine business unit, its product categories include immunohematology and donor screening. It provides diagnostic testing solutions under various brand names, including AdenoPlus, BIOVUE, FreshCells, InflammaDry, Lyra, MeterPro, MicroVue, Ortho, Ortho Clinical Diagnostics and Ortho Optix.
Employees
6,500
Date Price Change Volume
18/26/18 10.84 $ +5.04% 23,12,362
15/26/15 10.32 $ -9.39% 24,51,288
14/26/14 11.39 $ +3.08% 23,16,098
13/26/13 11.05 $ -0.63% 20,60,977
12/26/12 11.12 $ +11.65% 30,52,868
Trader
Investor
Global
Quality
ESG MSCI
A
Sell
Consensus
Buy
Mean consensus
HOLD
Number of Analysts
5
Last Close Price
10.84USD
Average target price
18.62USD
Spread / Average Target
+71.82%

Quarterly revenue - Rate of surprise